A Phase I/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases From Castration Resistant Prostate Cancer

Investigator: Charles J. Ryan, MD
Sponsor: Algeta ASA

Location(s): United States


The main purpose of this study is to establish a recommended dose of Alpharadin® to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and explore efficacy of the recommended dose.